Patient-based drug discovery's latest news
Myrtil Biotechnologies – our first Spin-off is born!
Based on our long-standing collaboration with myriamed GmbH and the successful establishment of an AI-powered screenable disease model for dilated cardiomyopathies, we proudly...
New publication: A step forward towards precision oncology
Ksilink is dedicated to foster patient-based therapeutic approaches including personalized strategies as a means to stratify potential targeted therapies in a clinically relevant...
Meet us in Denver
We will participate at this year’s Keystone Symposium on Modern Phenotypic Drug Discovery: From Chemical Biology to Therapy that will take place from May 22nd – May 25th 2022 in...
Ksilink engaged in EnvironMENTAL
Ksilink proudly takes part of the EC funded EnvironMENTAL consortium. Want to know more? You are invited to join a series of seminars! EnvironMENTAL aims at identifying the...
First success for Personalized Functional Profiling (PFP) of gastro-intestinal cancers
Ksilink proudly announces the publication of exciting results in the journal “Cancer Biology & Therapy”. In fact, the technology for Personalized Functional Profiling (PFP) of...
Journée de l’amitié franco-allemande/Tag der deutsch-französischen Freundschaft
A l'occasion de la journée de l'amitié franco-allemande, Ksilink vous présente ses meilleurs vœux pour l'année 2022 ! Version française Anlässlich des Tages der...
Ksilink wishes you all the best for 2022!
What you see here is neither a virtual firework nor has Ksilink become an expressionist. We took this beautiful picture, figuring the AI-based analysis of the pharmacological...
The ANR supports our efforts in drug discovery for Myotonic Dystrophy type 1
Ksilink is happy to announce the initiation of the ANR funded project "Target-agnostic drug discovery approaches for neuromuscular diseases (TREAD)". This project is supporting...
New solutions to treat Rubinstein-Taybi
Ksilink is happy to have welcomed the team of Prof. Valérie Mezger-Lallemand from Université Didérot to initiate a collaboration with the aim to establish a new patient-based disease model to identify …